Orforglipron (Foundayo): Oral GLP-1 Landscape and What’s Next

Orforglipron, sold as Foundayo, is Eli Lilly’s once-daily pill for weight management. The FDA approved it on April 1, 2026, which makes it the second oral GLP-1 medicine cleared in the US for obesity after Novo Nordisk’s Wegovy pill. For competitive-intelligence teams, the question has moved from “will an oral option exist” to how quickly it takes share, and what comes next in diabetes and abroad.

Mechanism at a glance

Orforglipron is a small-molecule GLP-1 receptor agonist taken by mouth, not a peptide. Per the FDA-approved information summarized by Lilly, it is one tablet once daily, with or without food, swallowed whole. Tablets come in strengths from 0.8 mg to 17.2 mg, and patients move up through doses over time. The label warns about thyroid C-cell tumors, and lists pancreatitis, gallbladder problems and dehydration among serious risks. Common side effects include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache and hair loss.

Why it matters

The FDA approved Foundayo for adults with obesity, or with overweight plus at least one weight-related condition, alongside diet and exercise. It was the first new molecular entity approved under the FDA’s Commissioner’s National Priority Voucher pilot: 50 days after filing and 294 days before its January 20, 2027 target date, which the agency called the fastest approval of a new molecular entity since 2002. The label is for obesity only; there is no US type 2 diabetes indication yet.

In ATTAIN-1 (3,127 adults without diabetes, 72 weeks), Lilly reported that the highest dose lost 12.4% of body weight versus 0.9% on placebo among people who stayed on treatment, and 11.1% versus 2.1% regardless of whether they stayed on treatment. Lilly’s launch release gave self-pay pricing from $149 per month for the lowest dose, and said prescriptions would be accepted through LillyDirect with shipping from April 6. Lilly reported Foundayo revenue of $184 million in the third quarter of 2026 and $281 million year to date.

Competitive pressure points

• Wegovy pill (Novo Nordisk): a 25 mg once-daily oral semaglutide approved in the US in late December 2025 and launched January 5, 2026. Novo reported more than 200,000 weekly prescriptions in the week ending April 17 and more than 2 million prescriptions since launch.
• Oral semaglutide in diabetes: in ACHIEVE-3, presented at the American Diabetes Association meeting in June 2026, Lilly reported larger A1C reductions with Foundayo (2.2% at 17.2 mg) than with oral semaglutide 14 mg (1.4%) over 52 weeks.
• Injectables: Lilly’s own Zepbound and Novo’s injectable products remain the efficacy benchmark, and retatrutide is next in line; see our retatrutide landscape.
• Other oral obesity candidates: we could not verify the status of other oral obesity drugs from primary sources for this article, so none are described here.

What to watch

• The US type 2 diabetes decision. On Lilly’s October 29 call, executives said the drug is under review for diabetes and the CFO said they expect regulatory action in Q4.
• Cardiovascular data. In ACHIEVE-4 (more than 2,700 adults with type 2 diabetes at elevated cardiovascular risk, versus insulin glargine), Lilly reported non-inferiority on major cardiovascular events, hazard ratio 0.84 (95% CI 0.59-1.20). That shows safety, not proven benefit.
• Ex-US approvals. Lilly says it has filed in more than 40 countries; on the Q3 call an executive said they hope a positive EU committee opinion leads to approval by year-end.
• Real-world uptake and pricing, including Medicare Part D access that Lilly said could start as soon as July 1, 2026 at $50 per month for eligible patients.

For other context, see obesity trial volume and survodutide.

Recent developments

Updated November 4, 2026. Items are drawn from company announcements, regulators and trade press; links go to the sources.

• Oct 29, 2026: Lilly reported Foundayo revenue of $184 million for the quarter, and said Foundayo showed cardiovascular safety and sustained A1C reduction in its largest and longest type 2 diabetes study. (Lilly 8-K; call transcript)
• Jun 8, 2026: Lilly presented ACHIEVE-2, -3 and -5 at ADA. Foundayo cut A1C by 1.7% versus 0.8% for Farxiga (40 weeks), and up to 2.1% versus 0.8% on placebo with insulin glargine. Lilly planned a diabetes submission in Q2. (BioSpace)
• Apr 16, 2026: Lilly announced ACHIEVE-4 topline results (see above). (American Pharmaceutical Review)
• Apr 1, 2026: FDA approved Foundayo for chronic weight management. (FDA; Lilly)
• Jan 5, 2026: Novo launched the Wegovy pill in the US. (Novo Nordisk Q1 report)
• Dec 23, 2025: Trade press reported the FDA approval of the Wegovy pill, the first oral GLP-1 for weight management. (BioSpace)

Upcoming catalysts

• Nov 14-17, 2026: ObesityWeek, National Harbor, Maryland. We did not find a Foundayo presentation announced for it.
• Dec 7, 2026: Lilly Innovation Day.
• Q4 2026: expected US regulatory action on type 2 diabetes, per Lilly’s CFO (an expectation, not a published FDA date).
• By end of 2026: hoped-for EU approval, per Lilly on its Q3 call.

Bottom line

Foundayo gives Lilly an oral option in obesity roughly three months after Novo’s, and early revenue is modest next to Lilly’s injectables. The next tests are a diabetes label, Europe, and head-to-head positioning against the Wegovy pill in real-world use.

Want this kind of analysis for the cardiovascular and metabolic areas you compete in? Request information and we will share sample deliverables.

This article is for informational and competitive-intelligence purposes only and is not medical advice. Approvals, labels and trial results change; verify details against current prescribing information and primary sources.